Proteinuria and VEGF-targeted therapies: an underestimated toxicity?
Oncologists and nephrologists usually manage proteinuria related to anti-vascular endothelial growth factor (anti-VEGF) treatment only when it is in the nephrotic range or associated with renal insufficiency. This report is based on our personal experience with 78 patients developing renal problems with anti-VEGF therapy. We found that proteinuria induced by anti-VEGF therapy, even if weak and without associated renal insufficiency, may reflect a serious histological renal disease.